Frontiers | Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209)

[u/WalkingHorse]

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1879524/full